Precision BioSciences is dedicated to improving life (DTIL) through the application of its pioneering, proprietary genome editing platform, ARCUS. Precision leverages ARCUS to develop product candidates in allogeneic (off-the-shelf) CAR T immunotherapy, in vivo gene correction, and food. Its lead clinical programs are currently in the allogeneic CAR T space with the most advanced product candidate being evaluated as a treatment for r/r NHL or B-ALL with initial results presented at ASH.